Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy

A Veeravagu, AR Hsu, W Cai, LC Hou… - Recent patents on …, 2007 - ingentaconnect.com
New blood vessel formation (angiogenesis) is fundamental to the process of tumor growth,
invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) …

Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy

TL Underiner, B Ruggeri… - Current medicinal …, 2004 - ingentaconnect.com
Among the known angiogenic growth factors and cytokines implicated in the modulation of
normal and pathological angiogenesis, the VEGF family (VEGF-A, VEGF-B, VEGF-C, VEGF …

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

JM Roodhart, MH Langenberg… - Current clinical …, 2008 - ingentaconnect.com
Vascular Endothelial Growth Factor (VEGF) is considered to be one of the most important
regulators of angiogenesis and a new key target in anti-cancer treatment. Various clinical …

The VEGF/VEGFR axis revisited: implications for cancer therapy

P Mabeta, V Steenkamp - International journal of molecular sciences, 2022 - mdpi.com
The vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor
(VEGFR) axis is indispensable in the process of angiogenesis and has been implicated as a …

A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis

S Baka, AR Clamp, GC Jayson - Expert opinion on therapeutic …, 2006 - Taylor & Francis
Angiogenesis plays an important role in the formation of new blood vessels and is crucial for
tumour development and progression. Imbalance between pro-and antiangiogenesis factors …

Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor

Y Zhao, AA Adjei - The oncologist, 2015 - academic.oup.com
Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …

Targeting EGFR and VEGF (R) pathway cross-talk in tumor survival and angiogenesis

AK Larsen, D Ouaret, K El Ouadrani… - Pharmacology & …, 2011 - Elsevier
The last decade has witnessed the approval of monoclonal antibodies (mAbs) and small
molecule tyrosine kinase inhibitors (TKIs) for targeting of oncogenic signaling pathways …

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy

S Takahashi - Biological and Pharmaceutical Bulletin, 2011 - jstage.jst.go.jp
Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) have crucial roles in
both physiological and pathological angiogenesis. The VEGF family consists of VEGF-A …

Resistance mechanisms to anti-angiogenic therapies in cancer

Y Haibe, M Kreidieh, H El Hajj, I Khalifeh… - Frontiers in …, 2020 - frontiersin.org
Tumor growth and metastasis rely on tumor vascular network for the adequate supply of
oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth …

E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models

E Bello, G Colella, V Scarlato, P Oliva, A Berndt… - Cancer research, 2011 - AACR
Tumor angiogenesis is a degenerate process regulated by a complex network of
proangiogenic factors. Existing antiangiogenic drugs used in clinic are characterized by …